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Apoptosis, Reduces Myocardial Troponin-I Cleavage,
Protects Left Ventricular Function, and Attenuates
Remodeling in Rats With Myocardial Infarction
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OBJECTIVES This study was designed to evaluate whether in vivo caspase inhibition can prevent myocardial
contractile protein degradation, improve myocardial function, and attenuate ventricular
remodeling.
BACKGROUND Apoptosis is thought to play an important role in the development and progression of heart
failure (HF) after a myocardial infarction (MI). However, it is not known whether inhibiting
apoptosis can attenuate left ventricular (LV) remodeling and minimize systolic dysfunction.
METHODS A 28-day infusion of caspase inhibitor (n  12) or vehicle (n  9) was administered to rats
immediately after an anterior MI. In addition, five sham-operated rats given the caspase
inhibitor were compared with 17 untreated sham-operated animals to study effects in non-MI
rats. Left ventricular function, remodeling parameters, and hemodynamics were studied four
weeks later. Myocardial caspase 3 activation and troponin-I contractile protein cleavage were
studied in the non-infarct, remote LV myocardium using Western blots. Apoptosis was
assessed using immunohistochemistry for activated caspase-positive cells as well as the
TUNEL method. Collagen volume was estimated using morphometry.
RESULTS Caspase inhibition reduced myocardial caspase 3 activation. This was accompanied by less
cleavage of troponin-I, an important component of the cardiac contractile apparatus, and
fewer apoptotic cardiomyocytes. Furthermore, caspase inhibition reduced LV-weight-to-
body-weight ratio, decreased myocardial interstitial collagen deposition, attenuated LV
remodeling, and better preserved LV systolic function after MI.
CONCLUSIONS Caspase inhibition, started soon after MI and continued for four weeks, preserves myocardial
contractile proteins, reduces systolic dysfunction, and attenuates ventricular remodeling.
These findings may have important therapeutic implications in post-MI HF. (J Am Coll
Cardiol 2004;43:295–301) © 2004 by the American College of Cardiology Foundation
A million and a half patients suffer a myocardial infarction
(MI) in the U.S. each year, and there are many times those
numbers with a pre-existing MI. Some 15% to 25% of these
patients develop heart failure (HF), which remains a pro-
gressive disease despite advances in pharmacologic therapy.
Ischemic cardiomyopathy is thus a large and rapidly grow-
ing burden. Methods to reduce the occurrence of HF after
MI are few and only modestly successful. The more effective
ones, such as those that improve myocardial perfusion (e.g.,
thrombolytic therapy or primary coronary angioplasty), have
their limitations, and the patient may be left with some
degree of left ventricular (LV) damage (1). It is possible that
a more direct approach, such as inhibiting cell death, could
reduce the occurrence of HF and improve prognosis. Tra-
ditionally, necrosis has been regarded as the pathologic
hallmark of myocardial cell death. However, there is accu-
mulating evidence that apoptosis contributes significantly to
myocardial cell death during and after MI (2–4). More
importantly, apoptosis may also contribute to the develop-
ment and progression of HF late after MI (5–7). Caspases
play a crucial role in myocardial apoptosis (8). There are
preliminary data that caspase inhibition can reduce apopto-
sis during ischemia and reperfusion with some beneficial
results (9–11). However, there are no data yet to clarify
whether inhibiting or attenuating apoptosis can reduce the
occurrence of HF or impede its progression after MI. In this
study, we show for the first time that long-term in vivo
caspase inhibition protects against myocardial contractile
protein cleavage and better preserves LV systolic function
after MI. Furthermore, in vivo caspase inhibition also
reduces non-infarct segment cardiomyocyte apoptosis and
attenuates ventricular remodeling in rats with MI.
MATERIALS AND METHODS
Animals and model. This study was done in adult male
Sprague-Dawley rats (200 to 250 g). Myocardial infarcts
were produced as previously described (12). Briefly, rats
were anesthetized (intraperitoneal sodium pentobarbital, 30
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mg/kg), and the proximal left coronary artery was surgically
occluded through a left thoracotomy. The suture was not
tied in rats serving as controls (sham group). The same
experienced surgical team, which has previously produced
consistently sized infarcts, operated on all the animals. The
protocol was approved by the institutional animal studies
committee, and animals were used in accordance with the
National Institutes of Health and institutional guidelines.
Caspase administration. Caspase inhibitor (Z-Asp-2,6
DCBMk, a cell-permeable, broad-spectrum caspase inhib-
itor that does not affect other cysteine proteases, Alexis
Biochemicals, San Diego, California) in dimethyl sulfoxide
(DMSO) or saline  DMSO was administered via a
peritoneal mini-pump in rats assigned to the caspase inhib-
itor (n 12) or vehicle (n 10, 9 rats completed the study)
treatment groups, respectively. The surgical team was
blinded to the contents of the pump. All rats in the caspase
treatment group received a 2 mg bolus of the drug imme-
diately before surgery (the control group received a bolus of
vehicle), and an infusion (2 mg/day) was started just after
coronary ligation. The infusion continued for 28 days after
the surgery. This dose was obtained from previous studies
(13) and our own pilot data. Hemodynamic and ventricular
remodeling data from caspase inhibitor or vehicle treated
rats were also compared with two additional separate groups
of rats: untreated MI (rats not given a pump or saline, n 
15) and sham-operated rats (rats where a suture was passed
under the left coronary artery but was not tied; n  17).
Measurements. All animals had the following measure-
ments. Tissues for Western blots and caspase staining were
obtained at one month after surgery from the non-infarct
remote myocardium of the LV.
Caspase activation and troponin-I cleavage. Caspase 3
activation and troponin I cleavage were assessed using
Western blots. Tissue samples were homogenized in a
Hepes buffer solution and a protease inhibitor cocktail
(Sigma, St. Louis, Missouri). After determining protein
concentrations, an equal amount of protein was added to
each well. SDS-PAGE was performed and completed gels
were transferred to nitrocellulose membrane in Towbin
buffer. The gels were blocked in 10% powdered milk, 3%
bovine serum albumin in TBS. Either rabbit anti-caspase-3
or goat anti-troponin-I or rabbit anti--actin (Santa Cruz
Biotechnology, Santa Cruz, California) was used as the
primary antibody. The secondary antibodies were
peroxidase-conjugated anti-rabbit and peroxidase-
conjugated anti-goat (Sigma). The Westerns were devel-
oped using Supersignal West Pico chemiluminescence de-
tection kit (Pierce, Rockford, Illinois). Blots were scanned,
and image analysis was done using the NIH Image J
program. Alpha-actin was used to normalize the test sam-
ples and serve as a loading control.
Cardiac apoptosis. This was evaluated by using two sepa-
rate techniques: 1) measuring the number of activated
caspase-positive cells in myocardial sections stained with
Apologix carboxyfluorescein caspase detection technique
(Cell Technology, Minneapolis, Minnesota); and 2)
TUNEL assay. The activated caspase detection technique
has been clearly validated to show in situ apoptosis (14,15).
Slides were labeled for activated caspases and counterstained
with hematoxylin and eosin. Cells positive for activated
caspase were counted in 30 random fields at 60 in each of
the animals. A person blinded to therapy did the staining
and counting. Even though the apoptosis-tagged
(Apologix) slides had a reasonably clear definition of cell
outline, a paired slide was also stained with hematoxylin and
eosin to outline the myocyte. Myocyte origin of Apologix-
positive apoptotic cells was confirmed by visualizing HE-
stained paired slides under high power. TUNEL staining
was done using the TACS-XL Blue Label kit (R and D
Systems, Minneapolis, Minnesota). TUNEL-positive cells
in 30 fields at 60 were counted in each animal. In view of
the problems associated with using TUNEL to define
apoptosis (16,17), the Apologix technique was used as the
primary measure of apoptosis, and TUNEL provided sec-
ondary validation about the trends in apoptosis.
Collagen distribution. The percent of area occupied by
collagen as opposed to non-collagen tissue was quantitated
in sections stained with Masson’s Trichrome using NIH J
image densitometry (18). Collagen volume fraction was
calculated as the sum of all collagen-positive areas divided
by the sum of muscle areas and collagen areas. This
approach estimates the proportion of myocardium occupied
by fibrillar collagen and closely correlates with the hy-
droxyproline concentration of the tissue (19).
Hemodynamics, LV systolic function, and LV remodel-
ing. Left ventricular remodeling was evaluated using echo-
cardiography at one and four weeks after surgery as previ-
ously described (12). Left ventricular systolic function was
assessed by in vivo hemodynamics (done at 4 weeks after
surgery) and by echocardiography (12). Ejection fraction
was measured using Simpson’s formula (20).
Statistical analysis. Comparisons between normally dis-
tributed parameters were assessed with a t test. A non-
parametric test (Mann-Whitney) was used for non-
normally distributed between group data. Multiple groups
(echocardiographic data) were compared using the analysis
of variance (ANOVA) module (STATISTICA, Sysoft Inc.,
Tulsa, Oklahoma, 1994). Post hoc tests were performed
using Bonferroni method when the ANOVA was signifi-
cant. A p value  0.05 was used for statistical significance.
All results are expressed as mean  SD.
Abbreviations and Acronyms
ANOVA  analysis of variance
DMSO  dimethyl sulfoxide
HF  heart failure
LV  left ventricle/ventricular
MI  myocardial infarction
296 Chandrashekhar et al. JACC Vol. 43, No. 2, 2004
Caspase Inhibition and Post-MI Remodeling January 21, 2004:295–301
RESULTS
The caspase inhibitor was given to five sham-operated rats
to see if the drug had any adverse effects on LV function or
remodeling in non-MI rats. Echo indices in sham-operated
animals given the drug were similar to sham-operated
animals not given the drug (LV internal dimension [dias-
tole]: 0.62  0.03 vs. 0.69  0.02; LV internal dimension
[systolic]: 0.35  0.03 vs. 0.34  0.03 and EF: 81  1.9 vs.
86  2.3 in sham-operated rats with and without caspase
inhibitor, respectively, all non-significant). Similarly, there
were no differences in hemodynamic measurements between
age-matched sham-operated animals treated with the
caspase inhibitor and those not given the drug. In the MI
group, although there was a 20% immediate surgical mor-
tality, there were no study drug-related deaths. A total of 12
rats given the caspase inhibitor and 10 rats given vehicle
alone survived the surgery. One rat in the saline group died
at one week during the echocardiographic study. All the
remaining rats (12 caspase inhibitor treated and 9 saline
treated) lived until sacrifice and completed the study. The
average infarct size, measured with morphometry, was
comparable (34% 5% and 37% 6% of LV in vehicle- vs.
caspase inhibitor treated rats) in both groups.
Caspase 3 activation. Therapy with the caspase inhibitor
significantly reduced caspase 3 activation, the main effector
caspase, in the LV myocardium from rats with MI. In
Western blots, caspase 3 cleavage was reduced by 55% in
caspase inhibitor treated compared with vehicle treated rats
(Fig. 1).
Cardiac apoptosis. Caspase 3 positivity predominantly in-
volved the cardiomyocytes, as evidenced by double staining-
activated Caspase 3 with either alpha sarcomeric actin or
hematoxylin and eosin, where the caspase 3 staining was
found within the outlines of apoptotic cardiomyocytes (Fig.
2A, panels A and B). Immunohistochemistry (Fig. 2A,
panels C and D) also showed that caspase inhibition
reduced myocyte apoptosis; there were 60% fewer caspase 3
positive cells in the remote LV myocardium of caspase
inhibitor treated rats than in vehicle treated rats (Fig. 2B)
(Mann-Whitney U test, p  0.001). TUNEL (Fig. 2A,
panels E and F) confirmed myocyte apoptosis and also
showed that the caspase inhibitor reduced cardiomyocyte
apoptosis.
Troponin-I cleavage. Caspase activation cleaves contrac-
tile proteins, and this may have implications for contractile
dysfunction. Caspase inhibition reduced troponin I cleavage
51% compared with vehicle treatment (Fig. 1).
Figure 1. (Top) Representative Western blot showing reduced caspase 3 and troponin-I cleavage in caspase inhibitor treated rats. Arrows identify the
cleaved fragment. (Bottom) Mean density units normalized to actin (n  8 each group) for caspase 3 and troponin-I cleaved fragments. Control  vehicle
treated rats.
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Hemodynamics. In vivo LV end-diastolic pressure (8 
0.9 vs. 13  1.6 mm Hg, p  0.05) was lower, whereas the
LV developed pressure trended to be higher (117  7 vs.
100  4 mm Hg, p  0.04) in caspase inhibitor treated rats
than in vehicle treated rats.
LV systolic function. Consistent with the reduced myo-
cardial troponin I cleavage seen in Figure 1, the caspase
inhibitor treatment significantly attenuated the decline in
systolic function seen after MI (Figs. 3 and 4). Ejection
fraction (39% and 46% greater at 1 and 4 weeks after MI, p
 0.05) and fractional shortening (55% and 45% greater at
1 and 4 weeks after MI, p  0.05) were better preserved
(Fig. 3) and LV end-systolic dimensions were 26% smaller
in caspase inhibitor treated animals than in either vehicle
treated or saline treated animals with MI (Fig. 4, lower
panel). Vehicle treated animals were no different from
animals with MI not given any infusion. Left ventricular
function, however, remained worse in caspase-inhibited
animals than in sham-operated animals. The mean arterial
pressure was similar in caspase inhibitor and vehicle treated
Figure 2. (A) Immunostaining for activated caspases in cardiomyocytes. Representative sections of left ventricular myocardium (200 to 400). The left
panel shows Apologix carboxyfluorescein activated caspase stain (white spots in panel A) and the same field stained with alpha sarcomeric actin (B) below.
Most of the apoptotic cells were myocytes. One fibroblast with apoptosis is also shown (arrowhead in panels A and B) and has a different morphology.
The next two panels show the effect of caspase inhibitors (caspase Rx) on number of apoptotic cells measured with Apologix staining (seen as large white
bright spots in panels C and D) or TUNEL (greenish color in panels E and F). There were fewer (panels C and E) activated caspase-positive cells (panel
C) or TUNEL-positive cells (panel E) in the myocardium of animals treated with caspase inhibitors than in the myocardium of animals with vehicle
treatment (no caspase Rx, panels D and F). (B) Mean data for the number of apoptotic cardiomyocytes from rats with myocardial infarction treated or
not treated with the caspase inhibitor (n  8 each group).
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animals (93  2.6 vs. 100  1.7 mm Hg, p  ns),
suggesting that the differences in systolic function were not
due to a vasodilator effect.
Myocardial interstitial collagen. The extent of myocardial
fibrosis in the vehicle treated animals was similar to that
described by other investigators in rats with moderately
large MIs (21). However, there was a 46% reduction in the
percentage of LV myocardium occupied by collagen in the
caspase inhibitor treated compared with the vehicle treated
rats (8%  0.7% vs. 15%  1.7%, p  0.05).
LV remodeling. Caspase inhibition attenuated LV remod-
eling, as assessed by a number of measures. Heart weight
was increased in both groups as expected after MI. How-
ever, heart weight and heart-weight-to-body-weight ratio
were significantly lower in the caspase inhibitor than in the
vehicle treated group (3.17  0.14 vs. 4.7  0.3, p 
0.028). The body weights were not significantly different
(336  3 vs. 342  2 g, p  ns, in caspase inhibitor vs.
vehicle treated animals). Echocardiographic LV end-
diastolic dimensions were lower in the caspase inhibitor
treated animals (Fig. 4, upper panel). These differences
persisted even when normalized to body weight. Echocar-
diographic LV mass tended to be lower in the caspase
inhibitor treated animals (0.57  0.04 g vs. 0.64  0.04 g),
once again suggesting reduced remodeling, but this was not
statistically significant.
DISCUSSION
We have shown for the first time that a four-week period of
in vivo caspase inhibition, starting immediately after MI,
reduced myocardial caspase 3 activation, is a crucial step in
mediating apoptosis (8). This was accompanied by less
cleavage of troponin-I, an important component of the
cardiac contractile apparatus. Furthermore, caspase inhibi-
tion modestly reduced ventricular fibrosis, attenuated ven-
tricular remodeling, and better preserved LV systolic func-
tion.
Cell loss and progression to HF after MI. The syndrome
of congestive HF is characterized by a relentless progression
and high mortality. Although the exact mechanisms respon-
sible for progression are not totally clear, it appears that
myocardial structural remodeling is an important predictor
of adverse prognosis in HF. Remodeling after MI is a
progressive, often self-perpetuating process, and cell loss
through apoptosis may be an important component in its
genesis (5–7). Increased wall stress and neurohormonal/
cytokine activation are known to adversely influence remod-
eling. There is evidence that these triggers can also mediate
apoptosis. Apoptotic cell loss may contribute to ventricular
dilation and increased wall stress, which may further per-
petuate HF (5,22). Thus, interruption of apoptosis may
have a therapeutic potential.
Apoptosis in MI and HF. Apoptosis has been shown to be
prominent in both animal (2,3) and human (4) MI. The
amount of apoptosis is variable and time dependent. There
is evidence for an increase in many of the apoptosis
intermediates, including a co-localization of caspase 3 and
apoptosis in the ischemic heart (8,23). Apoptosis is also
found in the chronically failing heart (6,7), albeit in a lesser
amount, and a progressive loss of myocytes through apo-
ptosis has been thought to be important for progression in
this syndrome (5). Some investigators have also found
chronic ongoing apoptosis in the hibernating heart, al-
though this is controversial (24).
Figure 3. Systolic function was better preserved both at one week and four
weeks after myocardial infarction (MI) in caspase inhibitor (CI) treated
(MI  CI, n  12) rats than in vehicle (dimethyl sulfoxide) treated (MI 
DMSO, n 9) rats or MI rats without any pump (untreated MI, n 15).
Systolic function still remained worse than in sham-operated animals (n 
17). EF  ejection fraction; FS  fractional shortening.
Figure 4. Left ventricular (LV) remodeling and function were improved in
rats with myocardial infarction (MI) given a caspase inhibitor (MI  CI,
n  12) for four weeks compared with vehicle (dimethyl sulfoxide) treated
(MI  DMSO, n  9) rats or MI rats without any pump (untreated MI,
n  15). Left ventricular remodeling still remained worse than in
sham-operated animals (n  17).
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Caspases and HF. Caspases, which are activated after MI
and in various stages of HF, are the key effector molecules
for apoptosis. Cellular caspases exist as inactive precursors
and need proteolytic cleavage for activation. They seem to
be a crucial step in myocardial apoptosis after MI (8). Caspase
activation co-localizes to apoptotic areas and precedes DNA
degradation and the development of apoptotic morphology
(23). Furthermore, caspase can also influence the contractile
machinery of myocytes through cleavage of troponin (25,26).
This can result in contractile dysfunction. Indeed, over-
expression of caspase 3 induces contractile dysfunction in mice
(27). However, caspase inhibition has not been studied in
depth for modifying the course of the failing heart.
Caspase inhibition in HF and MI. Although caspase
inhibitors have been tested in animal models of cardiac and
non-cardiac ischemia, there are no published studies that
have evaluated chronic caspase inhibition in the failing heart. A
few studies report the short-term effects of caspase inhibition in
MI (11,28). Caspase inhibition reduces apoptosis in experi-
mental models of ischemia-reperfusion, but the degree of
infarct size reduction is controversial (10,11). None of these
studies has evaluated longer-term effects of reducing apoptosis.
Our data is perhaps the first demonstration that long-term
caspase inhibition reduces cardiomyocyte apoptosis in the
non-infarct myocardium, attenuates systolic dysfunction, and
reduces ventricular remodeling after MI.
Cellular targets for improving ventricular remodeling. It
is interesting that caspase inhibition, apart from attenuating
ventricular dilation, also reduced myocardial fibrosis.
Caspase inhibition may have affected a variety of cells in the
remodeling myocardium, including cardiomyocytes, fibro-
blasts, endothelial cells, and even the inflammatory cell
infiltrate. Although anti-apoptotic effects on each of these
cell populations are likely to have complex and possibly
discordant effects on ventricular remodeling, the net effect in
our study was an attenuated LV remodeling. At the time we
measured apoptosis (4 weeks after MI), most of the apo-
ptotic cells appeared to be cardiomyocytes. This is consis-
tent with data in other models of HF (29) and even in hearts
with risk factors for myocardial ischemia but no failure (30).
There are no studies in literature to clarify how anti-
apoptotic therapy might affect various components of ven-
tricular remodeling. Our study also does not allow us to
determine how caspase inhibition therapy affected other cell
populations involved in ventricular remodeling and their
interactions in the remodeling process. Although reduction
in myocyte apoptosis could explain attenuated ventricular
remodeling, it is not clear whether blocking myofibroblast
apoptosis would be beneficial or harmful. Inhibiting myo-
fibroblast apoptosis could make the fragile granulation tissue
survive longer (31) and might make the scar tissue stronger.
This might prevent excessive ventricular dilation, and in-
deed, there is very recent evidence (32) supporting this using
ischemia-reperfusion—a model that, however, is signifi-
cantly different from our model. Anti-apoptotic effects on
fibroblasts early after MI have been suggested to retard
ventricular remodeling (33). Secondly, fibroblast death af-
fects the interconnection between myocytes, which would
be expected to increase myocyte slippage, enhance mural
thinning and chamber dilation, and increase wall stress
(29,33). All of these features worsen remodeling and could
be attenuated if anti-apoptotic therapy prolonged myofibro-
blast survival. This is supported by studies showing that
inhibiting collagen degradation attenuates LV remodeling
(34) and enhancing collagen degradation hastens the devel-
opment of HF (35). Thus the attenuated remodeling seen in
our model could be the result of beneficial effects on both
myocyte and non-myocyte components.
The reduction in non-infarct myocardial fibrosis that we
found at four weeks after MI in the caspase inhibitor group
may not, at first glance, be consistent with reduced fibro-
blast or myofibroblast apoptosis. However, the initial stim-
ulus to myofibroblast proliferation and increased fibrosis
may arise from increased regional wall stress or stretch and
neurohormonal activation (36). The latter would be atten-
uated if anti-apoptotic therapy reduced cardiomyocyte loss.
Moreover, anti-apoptotic effects on myofibroblasts, in the
critical initial days after MI, could have protected against
ventricular dilation and wall stress and thus reduced the
stimulus for fibrosis. Whereas our studies concentrated on
the net effects of anti-apoptotic therapy and were not
designed to tease out these individual elements, one could
speculate that reduced myocyte apoptosis (and possibly
reduced myofibroblast apoptosis in the early post-MI pe-
riod) might have reduced the stimuli for fibrous tissue
proliferation.
Study limitations. There are several limitations of this
study. Measurements including those for apoptosis were
made at four weeks after MI. Even though we did find
significant anti-apoptotic effects, earlier measurements
might have shown a larger difference in apoptosis. Caspases
also have beneficial housekeeping actions, and caspase
inhibition may result in unwanted consequences. These
were not evaluated in this study. Caspase inhibition may not
block all pro-apoptotic stimuli, and combined strategies,
attacking multiple pathways, may be more effective but
remain subject to future studies. We chose the dose from
previous studies in literature (13), but it is possible that a
higher dose may have had a greater effect on remodeling.
Finally, it is uncertain whether remodeling would worsen
once caspase inhibition is terminated. This is the subject of
a more long-term investigation.
Conclusions. We conclude that long-term caspase inhibi-
tion, started in the peri-MI period and continued for four
weeks, significantly inhibited non-infarct myocardial
caspase 3 activation and contractile protein cleavage in rats
with a large anterior wall MI. This was accompanied by
better preserved LV function and attenuated LV remodel-
ing. Caspase inhibition might have a therapeutic role in
improving the natural history of MI.
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